Nutrition and Phytotherapy: A Winning Combination Against Headache

Document Type : Narrative Review


Department of Pharmacy, University of Naples Federico II, Naples, Italy


Headache is an endemic, pathological disease that affects all individuals, regardless of age, gender, or social status. The causes of this phenomenon are many, and not all are known. Headaches vary in duration and severity and have a significant incidence in daily life. Pain is the main manifestation that can be associated with lacrimation, nausea, irritability, and dizziness. It is very difficult to find a specific treatment, and the medicaments used often have debilitating side effects that discourage their intake for long periods. Many doctors believe that proper nutrition and a healthy lifestyle as much as possible will offer more possibilities for preventing headaches and relieving painful symptoms. A valid help also comes from phytotherapy. Today the use of natural methods is more and more pleasing to patients, because they can continue the cure for a long time without the fear of undesirable effects. Many plants have been known since ancient times for their effectiveness in the treatment of migraine, and modern analytical methods have scientifically demonstrated the validity of their use and the mechanism of action of the effective active compounds present in them.


  1. Silberstein SD. Chronic daily headache. J Am Osteopath Assoc. 2005;105(4 Suppl 2):23s-29s.
  2. Ziegler DK, Hassanein RS. Specific headache phenomena: their frequency and coincidence. Headache. 1990;30(3):152-156. doi:10.1111/j.1526-4610.1990.hed3003152.x.
  3. Olesen J, Lipton RB. Headache classification update 2004. Curr Opin Neurol. 2004;17(3):275-282. doi:10.1097/00019052-200406000-00007.
  4. Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M. Quality of life in primary headache disorders: A review. Cephalalgia. 2016;36(1):67-91. doi:10.1177/0333102415580099.
  5. Karl HW, Trescot AM. Nerve Entrapment Headaches at the Temple: Zygomaticotemporal and/or Auriculotemporal Nerve? Pain Physician. 2019;22(1):E15-e36.
  6. Robbins MS, Lipton RB. The epidemiology of primary headache disorders. Semin Neurol. 2010;30(2):107-119. doi:10.1055/s-0030-1249220.
  7. Mathew PG, Garza I. Headache. Semin Neurol. 2011;31(1):5-17. doi:10.1055/s-0031-1271313.
  8. Lupi C, Benemei S, Guerzoni S, Pellesi L, Negro A. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opin Drug Metab Toxicol. 2019;15(3):189-198. doi:10.1080/17425255.2019.1578749.
  9. Tfelt-Hansen PC, Pihl T, Hougaard A, Mitsikostas DD. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs. 2014;23(3):375-385. doi:10.1517/13543784.2014.861817.
  10. Capi M, de Andres F, Lionetto L, et al. Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs. 2017;26(2):227-234. doi:10.1080/13543784.2017.1280457.
  11. Savi L, Rainero I, Valfre W, Gentile S, Lo Giudice R, Pinessi L. Food and headache attacks. A comparison of patients with migraine and tension-type headache. Panminerva Med. 2002;44(1):27-31.
  12. Holzhammer J, Wober C. Alimentary trigger factors that provoke migraine and tension-type headache. Schmerz. 2006;20(2):151- 159. doi:10.1007/s00482-005-0390-2.
  13. Jansen SC, van Dusseldorp M, Bottema KC, Dubois AE. Intolerance to dietary biogenic amines: a review. Ann Allergy Asthma Immunol. 2003;91(3):233-240; quiz 241-232, 296. doi:10.1016/S1081-1206(10)63523-5.
  14. Luthy J, Schlatter C. Biogenic amines in food: effects of histamine, tyramine and phenylethylamine in the human. Z Lebensm Unters Forsch. 1983;177(6):439-443. doi:10.1007/BF01409672.
  15. D’Andrea G, Terrazzino S, Fortin D, Cocco P, Balbi T, Leon A. Elusive amines and primary headaches: historical background and prospectives. Neurol Sci. 2003;24 Suppl 2:S65-67. doi:10.1007/ s100720300044.
  16. Martin VT, Vij B. Diet and headache: part 1. Headache. 2016;56(9):1543-1552. doi:10.1111/head.12953.
  17. Martin VT, Vij B. Diet and headache: Part 2. Headache. 2016;56(9):1553-1562. doi:10.1111/head.12952.
  18. le Grand SM, Supornsilpchai W, Saengjaroentham C, Srikiatkhachorn A. Serotonin depletion leads to cortical hyperexcitability and trigeminal nociceptive facilitation via the nitric oxide pathway. Headache. 2011;51(7):1152-1160. doi:10.1111/j.1526-4610.2011.01931.x.
  19. Supornsilpchai W, Sanguanrangsirikul S, Maneesri S, Srikiatkhachorn A. Serotonin depletion, cortical spreading depression, and trigeminal nociception. Headache. 2006;46(1):34- 39. doi:10.1111/j.1526-4610.2006.00310.x.
  20. Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology. 2004;63(11):2022-2027. doi:10.1212/WNL.65.1.180.
  21. Bird N, MacGregor EA, Wilkinson MI. Ice cream headache--site, duration, and relationship to migraine. Headache. 1992;32(1):35- 38. doi:10.1111/j.1526-4610.1992.hed3201035.x.
  22. Panconesi A. Alcohol and migraine: trigger factor, consumption, mechanisms. A review. J Headache Pain. 2008;9(1):19-27. doi:10.1007/s10194-008-0006-1.
  23. Peatfield RC. Relationships between food, wine, and beer-precipitated migrainous headaches. Headache. 1995;35(6):355- 357. doi:10.1111/j.1526-4610.1995.hed3506355.x.
  24. Finocchi C, Sivori G. Food as trigger and aggravating factor of migraine. Neurol Sci. 2012;33 Suppl 1:S77-80. doi:10.1007/s10072-012-1046-5.
  25. Campbell DA, Hay KM, Tonks EM. An investigation of the salt and water balance in migraine. Br Med J. 1951;2(4745):1424-1429. doi:10.1136/bmj.2.4745.1424.
  26. Orr SL. Diet and nutraceutical interventions for headache management: A review of the evidence. Cephalalgia. 2016;36(12):1112-1133. doi:10.1177/0333102415590239.
  27. Torelli P, Manzoni GC. Fasting headache. Curr Pain Headache Rep. 2010;14(4):284-291. doi:10.1007/s11916-010-0119-5.
  28. Walter S. Lifestyle behaviors and illness-related factors as predictors of recurrent headache in U.S. adolescents. J Neurosci Nurs. 2014;46(6):337-350. doi:10.1097/JNN.0000000000000095.
  29. De Weerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3(3):225-230. doi:10.1016/S0944-7113(96)80057-2.
  30. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia. 1993;13(3):151-165. doi:10.1046/j.1468-2982.1993.1303151.x.
  31. Plateariuo JG. Practica brevis: un manuale di medicina pratica del XII secolo. Tuscania: Penne & Papyri; 2015.
  32. Presley CC, Lindsley CW. DARK Classics in Chemical Neuroscience: Opium, a Historical Perspective. ACS Chem Neurosci. 2018;9(10):2503-2518. doi:10.1021/acschemneuro.8b00459.
  33. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949. doi:10.1126/science.1470919.
  34. Lochte BC, Beletsky A, Samuel NK, Grant I. The use of cannabis for headache disorders. Cannabis Cannabinoid Res. 2017;2(1):61-71. doi:10.1089/can.2016.0033.
  35. Kim PS, Fishman MA. Cannabis for pain and headaches: primer. Curr Pain Headache Rep. 2017;21(4):19. doi:10.1007/s11916-017-0619-7.
  36. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been. Headache. 2015;55(6):885-916. doi:10.1111/head.12570.
  37. Germano A, Occhipinti A, Barbero F, Maffei ME. A pilot study on bioactive constituents and analgesic effects of MyrLiq®, a Commiphora myrrha extract with a high furanodiene content. Biomed Res Int. 2017;2017:3804356. doi:10.1155/2017/3804356.
  38. Morteza-Semnani K, Saeedi M. Constituents of the essential oil of Commiphora myrrha (Nees) Engl. var. molmol. J Essent Oil Res. 2003;15(1):50-51. doi:10.1080/10412905.2003.9712264.
  39. Hanus LO, Rezanka T, Dembitsky VM, Moussaieff A. Myrrh-commiphora chemistry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005;149(1):3-27. doi:10.5507/bp.2005.001.
  40. Shen T, Li GH, Wang XN, Lou HX. The genus Commiphora: a review of its traditional uses, phytochemistry and pharmacology. J Ethnopharmacol. 2012;142(2):319-330. doi:10.1016/j.jep.2012.05.025.
  41. Foushee DB, Ruffin J, Banerjee U. Garlic as a natural agent for the treatment of hypertension: a preliminary report. Cytobios. 1982;34(135-36):145-152.
  42. Reuter HD. Allium sativum and Allium ursinum: Part 2 pharmacology and medicinal application. Phytomedicine. 1995;2(1):73-91. doi:10.1016/S0944-7113(11)80052-8.
  43. Majewski M. Allium sativum: facts and myths regarding human health. Rocz Panstw Zakl Hig. 2014;65(1):1-8.
  44. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed). 1985;291(6495):569-573. doi:10.1136/bmj.291.6495.569.
  45. Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J Pharm Pharmacol. 1987;39(6):459-465. doi:10.1111/j.2042-7158.1987.tb03420.x.
  46. Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol. 1992;44(5):391-395. doi:10.1111/j.2042-7158.1992.tb03631.x.
  47. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia. 1998;18(10):704- 708. doi:10.1046/j.1468-2982.1998.1810704.x.
  48. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2(8604):189-192. doi:10.1016/S0140-6736(88)92289-1.
  49. Pittler MH, Vogler BK, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2000(3):Cd002286. doi:10.1002/14651858.CD002286.
  50. Grant L, McBean DE, Fyfe L, Warnock AM. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytother Res. 2007;21(3):199-209. doi:10.1002/ptr.2029.
  51. Barnes J, Anderson LA, Phillipson JD. Herbal medicines. 3rd ed. Pharmaceutical Press; 2007:207-214.
  52. Brien S, Lewith GT, McGregor G. Devil’s Claw (Harpagophytum procumbens) as a treatment for osteoarthritis: a review of efficacy and safety. J Altern Complement Med. 2006;12(10):981-993. doi:10.1089/acm.2006.12.981.
  53. Setty AR, Sigal LH. Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Semin Arthritis Rheum. 2005;34(6):773-784. doi:10.1016/j.semarthrit.2005.01.011.
  54. Grant L, McBean DE, Fyfe L, Warnock AM. The inhibition of free radical generation by preparations of Harpagophytum procumbens in vitro. Phytother Res. 2009;23(1):104-110. doi:10.1002/ptr.2570.
  55. Rāzī ABMZ, Ḍinnawī MA. Man of La yaḥduruhu al-Tabib aw qabl ṭabībuk wusūl al-Tabib. Bayrūt: Dār al-Kutub al-Ilmiyah; al-Ṭab’ah 1; 1999.
  56. Derry S, Wiffen PJ, Moore RA. Aspirin for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev. 2017;1:Cd011888. doi:10.1002/14651858.CD011888. pub2.
  57. Lampl C, Voelker M, Steiner TJ. Aspirin is first-line treatment for migraine and episodic tension-type headache regardless of headache intensity. Headache. 2012;52(1):48-56. doi:10.1111/j.1526-4610.2011.01974.x.
  58. Gaciong Z. The real dimension of analgesic activity of aspirin. Thromb Res. 2003;110(5-6):361-364. doi:10.1016/j.thromres.2003.08.009.
  59. Fonseca DV, Salgado PR, Aragao Neto Hde C, et al. Ortho-eugenol exhibits anti-nociceptive and anti-inflammatory activities. Int Immunopharmacol. 2016;38:402-408. doi:10.1016/j.intimp.2016.06.005.
  60. Fujisawa S, Murakami Y. Eugenol and Its Role in Chronic Diseases. Adv Exp Med Biol. 2016;929:45-66. doi:10.1007/978-3-319-41342-6_3.
  61. Dal Bo W, Luiz AP, Martins DF, Mazzardo-Martins L, Santos AR. Eugenol reduces acute pain in mice by modulating the glutamatergic and tumor necrosis factor alpha (TNF-alpha) pathways. Fundam Clin Pharmacol. 2013;27(5):517-525. doi:10.1111/j.1472-8206.2012.01052.x.
  62. Sarmento-Neto JF, do Nascimento LG, Felipe CF, de Sousa DP. Analgesic potential of essential oils. Molecules. 2015;21(1):E20. doi:10.3390/molecules21010020.
  63. Hajhashemi V, Ghannadi A, Sharif B. Anti-inflammatory and analgesic properties of the leaf extracts and essential oil of Lavandula angustifolia Mill. J Ethnopharmacol. 2003;89(1):67-71. doi:10.1016/S0378-8741(03)00234-4.
  64. Srivastava KC, Mustafa T. Ginger (Zingiber officinale) and rheumatic disorders. Med Hypotheses. 1989;29(1):25-28. doi:10.1016/0306-9877(89)90162-X.
  65. Mustafa T, Srivastava KC. Ginger (Zingiber officinale) in migraine headache. J Ethnopharmacol. 1990;29(3):267-273. doi:10.1016/0378-8741(90)90037-T.
  66. Raghavendra RH, Naidu KA. Spice active principles as the inhibitors of human platelet aggregation and thromboxane biosynthesis. Prostaglandins Leukot Essent Fatty Acids. 2009;81(1):73-78. doi:10.1016/j.plefa.2009.04.009.
  67. Hosseinzadeh H, Younesi HM. Antinociceptive and anti-inflammatory effects of Crocus sativus L. stigma and petal extracts in mice. BMC Pharmacol. 2002;2:7. doi:10.1186/1471-2210-2-7.
  68. Srivastava KC. Antiplatelet principles from a food spice clove (Syzygium aromaticum L) [corrected]. Prostaglandins Leukot Essent Fatty Acids. 1993;48(5):363-372. doi:10.1016/0952-3278(93)90116-E.
  69. Suneetha WJ, Krishnakantha TP. Antiplatelet activity of coriander and curry leaf spices. Pharm Biol. 2005;43(3):230-233. doi:10.1080/13880200590928807.
  70. Ikram M, Shafi N, Mir I, Do MN, Nguyen P, Le Quesne PW. 24zeta-Ethylcholesta-7,22-Dien-3beta-ol: A Possibly Antipyretic Constituent of Artemisia absinthium. Planta Med. 1987;53(4):389. doi:10.1055/s-2006-962748.
  71. Khattak SG, Gilani SN, Ikram M. Antipyretic studies on some indigenous Pakistani medicinal plants. J Ethnopharmacol. 1985;14(1):45-51. doi:10.1016/0378-8741(85)90027-3.
  72. Lee HG, Kim H, Oh WK, et al. Tetramethoxy hydroxyflavone p7F downregulates inflammatory mediators via the inhibition of nuclear factor kappaB. Ann N Y Acad Sci. 2004;1030:555-568. doi:10.1196/annals.1329.065.
  73. Lopes-Lutz D, Alviano DS, Alviano CS, Kolodziejczyk PP. Screening of chemical composition, antimicrobial and antioxidant activities of Artemisia essential oils. Phytochemistry. 2008;69(8):1732-1738. doi:10.1016/j.phytochem.2008.02.014.
  74. Lampl C, Haider B, Schweiger C. Long-term efficacy of Boswellia serrata in four patients with chronic cluster headache. Cephalalgia. 2012;32(9):719-722. doi:10.1177/0333102412451357.
  75. Ammon HP. Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases. Wien Med Wochenschr. 2002;152(15-16):373-378. doi:10.1046/j.1563-258X.2002.02056.x.
  76. Grice ID, Rogers KL, Griffiths LR. Isolation of bioactive compounds that relate to the anti-platelet activity of Cymbopogon ambiguus. Evid Based Complement Alternat Med. 2011;2011:467134. doi:10.1093/ecam/nep213.